Abstract PS13-31: Prospective observational study to explore the effectiveness of eribulin as first- or second- line chemotherapy in patients with HER2-negative hormone-resistant advanced or metastatic breast cancer (KBCRN A001: E-SPEC study)

2021 ◽  
Author(s):  
Yuri Fujimoto ◽  
Yuichiro Kikawa ◽  
Takeshi Kotake ◽  
Shigeru Tsuyuki ◽  
Sachiko Takahara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Metastatic Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer

2007 ◽  
Vol 134 (2) ◽  
pp. 125-135 ◽  
Author(s):  
Martina Baur ◽  
Allan T. van Oosterom ◽  
Véronique Diéras ◽  
Michele Tubiana-Hulin ◽  
R. Charles Coombes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer

1996 ◽  
Vol 10 (5) ◽  
pp. 504-521 ◽  
Author(s):  
Robert Launois ◽  
Jeanne Reboul-Marty ◽  
Bernadette Henry ◽  
Jacques Bonneterre
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Second Line ◽  
Utility Analysis ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

P917. Taxol and fluorouracil as second line chemotherapy for metastatic breast cancer

The Breast ◽  
1997 ◽  
Vol 6 (5) ◽  
pp. 335
Author(s):  
A. Fornasiero ◽  
C. Ghiotto ◽  
O. Daniele ◽  
P. D'Amanzo ◽  
S.M.L. Aversa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document